| 000 | 01902 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250518065455.0 | ||
| 264 | 0 | _c20201016 | |
| 008 | 202010s 0 0 eng d | ||
| 022 | _a1873-4847 | ||
| 024 | 7 |
_a10.1016/j.jnutbio.2019.108227 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWu, Chi-Shiuan | |
| 245 | 0 | 0 |
_aCurcumin functions as a MEK inhibitor to induce a synthetic lethal effect on KRAS mutant colorectal cancer cells receiving targeted drug regorafenib. _h[electronic resource] |
| 260 |
_bThe Journal of nutritional biochemistry _c12 2019 |
||
| 300 |
_a108227 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aButadienes _xpharmacology |
| 650 | 0 | 4 |
_aColorectal Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aCurcumin _xadministration & dosage |
| 650 | 0 | 4 |
_aGene Expression Regulation, Neoplastic _xdrug effects |
| 650 | 0 | 4 | _aHCT116 Cells |
| 650 | 0 | 4 | _aHT29 Cells |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMAP Kinase Kinase Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aNitriles _xpharmacology |
| 650 | 0 | 4 |
_aPhenylurea Compounds _xadministration & dosage |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins p21(ras) _xgenetics |
| 650 | 0 | 4 |
_aPyridines _xadministration & dosage |
| 700 | 1 | _aWu, Shan-Ying | |
| 700 | 1 | _aChen, Hsin-Chih | |
| 700 | 1 | _aChu, Chien-An | |
| 700 | 1 | _aTang, Han-Hsuan | |
| 700 | 1 | _aLiu, Hsiao-Sheng | |
| 700 | 1 | _aHong, Yi-Ren | |
| 700 | 1 | _aHuang, Chi-Ying F | |
| 700 | 1 | _aHuang, Guan-Cheng | |
| 700 | 1 | _aSu, Chun-Li | |
| 773 | 0 |
_tThe Journal of nutritional biochemistry _gvol. 74 _gp. 108227 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jnutbio.2019.108227 _zAvailable from publisher's website |
| 999 |
_c30262438 _d30262438 |
||